HS-173, a novel PI3K inhibitor enhances radiosensitivity of breast cancer cells

Background: The development of radiosensitizers that modulate activated signaling pathways has enhanced effective cancer treatment via radiation therapy. phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT) pathway induces progression and radioresistance. Therefore, we investigated if HS-173, a novel PI3K inhibitor, could increase the radiosensitivity in breast cells. Materials Methods: Breast cell lines (MCF-7, BT-474, T47D, MDA-MB-231) were exposed to (2–8 Gy). After irradiation, viability was assessed using MTT assay. MDA-MB-231 cells (5 Gy) alone and/or combination with HS-173 (1 μM). treatment, levels PI3K/AKT protein measured western blotting. clonogenic assay flow cytometry. Results: We observed decreased radiation-induced phosphorylation AKT increased their Upon investigation mechanism underlying by significant IR-induced G2/M cycle arrest apoptosis components, including poly (ADP-ribose) polymerase (PARP-1) cleaved caspase-3. It can be concluded significantly improved inducing radio-resistant Conclusion: may applied as radiosensitizer promising potential treatment.